| Autor: |
Schutt SD; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Fu J; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America; Cancer Biology PhD Program, University of South Florida and H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America., Nguyen H; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Bastian D; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Heinrichs J; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Wu Y; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Liu C; Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, United States of America., McDonald DG; Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina, United States of America., Pidala J; Blood and Bone Marrow Transplant Department, Moffitt Cancer Center, Tampa, Florida, United States of America., Yu XZ; Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America. |
| Abstrakt: |
Bruton's Tyrosine Kinase (BTK) and IL-2 Inducible T-cell Kinase (ITK) are enzymes responsible for the phosphorylation and activation of downstream effectors in the B-cell receptor (BCR) signaling and T cell receptor (TCR) signaling pathways, respectively. Ibrutinib is an FDA-approved potent inhibitor of both BTK and ITK that impairs B-cell and T-cell function. CD4 T cells and B cells are essential for the induction of chronic graft-versus-host disease (cGVHD). We evaluated these targets by testing the ability of Ibrutinib to prevent or ameliorate cGVHD, which is one of the major complications for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We found that Ibrutinib significantly alleviated cGVHD across four different mouse models, accompanied by increased long-term survival and reduced clinical score. The clinical improvements in Ibrutinib-treated recipients were associated with decreased serum-autoantibodies, costimulatory molecule activation, B-cell proliferation, and glomerulonephritis compared to vehicle controls. Ibrutinib was also able to alleviate the clinical manifestations in acute GVHD (aGVHD), where the recipients were given grafts with or without B cells, suggesting that an inhibitory effect of Ibrutinib on T cells contributes to a reduction in both aGVHD and cGVHD pathogenesis. An effective prophylactic regimen is still lacking to both reduce the incidence and severity of human cGVHD following allo-HSCT. Our study shows that Ibrutinib is an effective prophylaxis against several mouse models of cGVHD with minimal toxicity and could be a promising strategy to combat human cGVHD clinically. |
